Sugi Predict

Sugi Predict / Compounds / SCHEMBL5201714

SCHEMBL5201714

SCHEMBL5201714

O=C1C=C2CCCCC2CC1

nearest known ligand 0.55

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ TLR4 O00206 2/20 0.55
▸ ESR2 Q92731 2/20 0.37
▸ MAOA P21397 1/20 0.36
▸ MAOB P27338 1/20 0.36
▸ CA1 P00915 1/20 0.32
▸ CA2 P00918 1/20 0.32
▸ CA4 P22748 1/20 0.32
▸ MMP2 P08253 1/20 0.32
▸ PTPN1 P18031 2/20 0.32
▸ DAO P14920 2/20 0.31
▸ KMT2A Q03164 1/20 0.31
▸ CYP19A1 P11511 2/20 0.31
▸ SLC18A3 Q16572 1/20 0.31
▸ MAPT P10636 2/20 0.31
▸ PTPRC P08575 1/20 0.31
▸ PTPRF P10586 1/20 0.31
▸ CDC25B P30305 1/20 0.31
▸ GAA P10253 1/20 0.30
▸ RAB9A P51151 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11181948 0.93 TLR4 (0.47) TLR4ESR2MAOAMAOBMMP2
SCHEMBL9609547 0.87 TLR4 (0.50) TLR4MAOAMAOBPTPN1DAO
SCHEMBL7644421 0.87 TLR4 (0.50) TLR4MAOAMAOBCA1CA2
SCHEMBL1021749 0.86 TLR4 (0.53) TLR4ESR2MAOAMAOBMMP2
SCHEMBL10975419 0.86 — —
SCHEMBL15380945 0.86 TLR4 (0.42) TLR4ESR2MMP2MAPT
SCHEMBL7638703 0.85 TLR4 (0.48) TLR4MAOAMAOBCA1CA2
SCHEMBL7640330 0.85 TLR4 (0.48) TLR4MAOAMAOBCA1CA2
SCHEMBL7640959 0.85 TLR4 (0.48) TLR4MAOAMAOBCA1CA2
SCHEMBL7640144 0.85 TLR4 (0.48) TLR4MAOAMAOBCA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1841723-A1 DECALINE DERIVED COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS Universität Dortmund (DE) 2007-10-10 — — EP claimed
WO-2006069787-A1 DECALINE-DERIVED COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS Universität Dortmund (DE) 2006-07-06 — — WO claimed
US-20250346581-A1 PROCESS FOR SYNTHESIS OF GALBULIMIMA ALKALOID 18 AND COMPOUNDS USEFUL AS OPIOID RECEPTOR ANTAGONISTS AND AGONISTS SCRIPPS RESEARCH INST (US) 2025-11-13 — — US disclosed
US-20250186646-A1 Use of Volatile Compositions to Limit or Eliminate Perception of Fecal Malodour FIRMENICH SA (CH) 2025-06-12 — — US disclosed
US-20250066693-A1 COMPOSITION KAO CORPORATION (JP) 2025-02-27 — — US disclosed
US-20250051696-A1 DETERGENT COMPOSITION KAO CORPORATION (JP) 2025-02-13 — — US disclosed
EP-4455257-A1 CLEANING AGENT COMPOSITION Kao Corporation (JP) 2024-10-30 — — EP disclosed
EP-4454715-A1 COMPOSITION Kao Corporation (JP) 2024-10-30 — — EP disclosed
US-11744785-B2 Use of volatile compositions to limit or eliminate the perception of malodor FIRMENICH SA (CH) 2023-09-05 — — US disclosed
WO-2023141593-A2 PROCESS FOR SYNTHESIS OF GALBULIMIMA ALKALOID 18 AND COMPOUNDS USEFUL AS OPIOID RECEPTOR ANTAGONISTS AND AGONISTS THE SCRIPPS RESEARCH INSTITUTE (US) 2023-07-27 — — WO disclosed
WO-2023141593-A2 PROCESS FOR SYNTHESIS OF GALBULIMIMA ALKALOID 18 AND COMPOUNDS USEFUL AS OPIOID RECEPTOR ANTAGONISTS AND AGONISTS THE SCRIPPS RESEARCH INSTITUTE (US) 2023-07-27 — — WO disclosed
US-8809567-B2 Method for producing silylenol ethers KYOTO UNIVERSITY (JP) 2014-08-19 — — US disclosed
US-20130053567-A1 METHOD FOR PRODUCING SILYLENOL ETHERS KYOTO UNIVERSITY (JP) 2013-02-28 — — US disclosed
US-20130053567-A1 METHOD FOR PRODUCING SILYLENOL ETHERS KYOTO UNIVERSITY (JP) 2013-02-28 — — US disclosed
EP-2543674-A1 METHOD FOR PRODUCING SILYLENOL ETHERS Kyoto University (JP) 2013-01-09 — — EP disclosed
EP-2319621-A2 Base stable ionic liquids The Queen's University of Belfast (GB) 2011-05-11 — — EP disclosed
US-20090216015-A1 Base Stable Ionic Liquids THE QUEEN'S UNIVERSITY OF BELFAST (GB) 2009-08-27 — — US disclosed
US-20090216015-A1 Base Stable Ionic Liquids THE QUEEN'S UNIVERSITY OF BELFAST (GB) 2009-08-27 — — US disclosed
US-5484806-A 4-HYDROXY-2-PYRROLIDONE DERIVATIVES; ANTIINFLAMMATORY AGENTS AMERICAN HOME PRODUCTS CORPORATION (US) 1996-01-16 — — US disclosed
US-5428058-A Antiinflammatory agents AMERICAN HOME PRODUCTS CORPORATION (US) 1995-06-27 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11744785-B2 Use of volatile compositions to limit or eliminate the perception of malodor TAS2R8, TRPA1, TAS2R10 TLR4 190/4885ESR2 4244/4885MAOA 156/4885
US-20130053567-A1 METHOD FOR PRODUCING SILYLENOL ETHERS AKR7A2, MSMO1, CYP2E1 TLR4 4307/4885ESR2 1342/4885MAOA 2523/4885
US-20250346581-A1 PROCESS FOR SYNTHESIS OF GALBULIMIMA ALKALOID 18 AND COMPOUNDS USEFUL AS OPIOID RECEPTOR ANTAGONISTS AND AGONISTS OPRM1, OGFR, OPRK1 TLR4 2105/4885ESR2 2282/4885MAOA 420/4885
US-20090216015-A1 Base Stable Ionic Liquids BRAF, TIAL1, HPRT1 TLR4 4457/4885ESR2 4426/4885MAOA 2923/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.